The company reported a significant improvement in its financial performance for 2023, with net losses decreasing to $29.8M from $95.3M in 2022. Research expenses dramatically reduced to $13 from $159 in the previous year. However, the company's cash position remains critical at $38,000 as of December 31, 2023.The firm has secured several strategic financing arrangements, including a $5M stock purchase agreement with ClearThink, a $110,000 convertible note from LGH Investments, and a $750 promissory note at 12% interest. A notable strategic partnership was established with KR8 AI in January 2024, involving a Master Software Agreement for epigenetic biomarker technology and the issuance of 1.3M shares of Class A Common Stock.The company faces significant challenges, including going concern issues beyond Q3 2024 and NYSE American listing compliance requirements. Material weaknesses in internal controls persist, while multiple financing arrangements carry dilutive potential. The firm continues its research collaboration with CHOP for DNA methylation array software and is developing AI machine learning applications for health and wellness.

The company reported a significant improvement in its financial performance for 2023, with net losses decreasing to $29.8M from $95.3M in 2022. Research expenses dramatically reduced to $13 from $159 in the previous year. However, the company's cash position remains critical at $38,000 as of December 31, 2023.The firm has secured several strategic financing arrangements, including a $5M stock purchase agreement with ClearThink, a $110,000 convertible note from LGH Investments, and a $750 promissory note at 12% interest. A notable strategic partnership was established with KR8 AI in January 2024, involving a Master Software Agreement for epigenetic biomarker technology and the issuance of 1.3M shares of Class A Common Stock.The company faces significant challenges, including going concern issues beyond Q3 2024 and NYSE American listing compliance requirements. Material weaknesses in internal controls persist, while multiple financing arrangements carry dilutive potential. The firm continues its research collaboration with CHOP for DNA methylation array software and is developing AI machine learning applications for health and wellness.